Why the study?
IMR and HMR are proposed invasive indexes of microvascular resistance for diagnosing severe CMVD after pPCI in STEMI, but they are not routinely assessed and their association with long-term MACE required clarification.
Does severe coronary microvascular dysfunction (assessed by IMR or HMR) increase the risk of long-term major adverse cardiovascular events in patients with STEMI post-PCI?
Does severe coronary microvascular dysfunction (assessed by IMR or HMR) increase the risk of long-term major adverse cardiovascular events in patients with STEMI post-PCI?
Severe coronary microvascular dysfunction assessed by IMR or HMR post-PCI in STEMI patients is a powerful prognostic marker associated with a >3-fold increased risk of long-term MACE.
Answers are grounded in this paper and cite their sources.
Supports CMVD assessment for post-PCI risk stratification in STEMI; leaves open whether targeted therapy reduces MACE.
Coronary microvascular dysfunction (CMVD) is common and associated with poorer outcomes in patients with ST Segment Elevation Myocardial Infarction (STEMI). The index of microcirculatory resistance (IMR) and the index of hyperemic microvascular resistance (HMR) are both invasive indexes of microvascular resistance proposed for the diagnosis of severe CMVD after primary percutaneous coronary intervention (pPCI). However, these indexes are not routinely assessed in STEMI patients. Our main objective was to clarify the association between IMR or HMR and long-term major adverse cardiovascular events (MACE), through a systematic review and meta-analysis of observational studies. We searched Medline, PubMed, and Google Scholar for studies published in English until December 2020. The primary outcome was a composite of cardiovascular death, non-cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and rehospitalization for heart failure occurring after at least 6 months following CMVD assessment. We identified 6 studies, reporting outcomes in 1094 patients (mean age 59.7 ± 11.4 years; 18.2% of patients were women) followed-up from 6 months to 7 years. Severe CMVD, defined as IMR > 40 mmHg or HMR > 3mmHg/cm/sec was associated with MACE with a pooled HR of 3.42 [2.45; 4.79]. Severe CMVD is associated with an increased risk of long-term adverse cardiovascular events in patients with STEMI. Our results suggest that IMR and HMR are useful for the early identification of severe CMVD in patients with STEMI after PCI, and represent powerful prognostic assessments as well as new therapeutic targets for clinical intervention.
No takes yet. Share an insight, caveat, or question.
Canu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: